Current stage-Stage I Posts on Medivizor
Navigation Menu

Current stage-Stage I Posts on Medivizor

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Posted by on Jul 2, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the...

Read More

Evaluating the effectiveness and safety of robotic versus laparoscopic resections for patients with low rectal cancer.

Evaluating the effectiveness and safety of robotic versus laparoscopic resections for patients with low rectal cancer.

Posted by on Feb 27, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of robotic versus laparoscopic abdominoperineal resections (APRs) for the treatment of patients with low rectal cancer (RC). The data showed that robotic APRs significantly reduced surgical trauma and promoted recovery after surgery compared with laparoscopic APRs in these patients. Some...

Read More

Evaluating the effectiveness and safety of transanal versus laparoscopic total mesorectal resection for the treatment of patients with rectal cancer.

Evaluating the effectiveness and safety of transanal versus laparoscopic total mesorectal resection for the treatment of patients with rectal cancer.

Posted by on Jan 8, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of transanal (ta) versus laparoscopic (lap) total mesorectal resection (TME) for the treatment of patients with stage I-III rectal cancer (RC). The data showed that experienced surgeons can safely perform taTME in these patients. Some background Rectal cancer (RC) is one of the most...

Read More

Evaluating the effectiveness of transanal endoscopic microsurgery for the treatment of early rectal cancer in patients over 60 years old with high surgical risk.

Evaluating the effectiveness of transanal endoscopic microsurgery for the treatment of early rectal cancer in patients over 60 years old with high surgical risk.

Posted by on Jan 3, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of transanal endoscopic microsurgery (TEM) for the treatment of early rectal cancer (RC) in patients over 60 years old with high surgical risk. The data showed that TEM is a reliable and effective treatment option in high-risk patients over 60 years old. Some background Rectal cancer (RC) is one of...

Read More

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Posted by on Apr 26, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the oncological effectiveness of intraoperative radiotherapy (IORT) and whole breast irradiation (WBI) for patients with early breast cancer (BC).  This study concluded that there was a high oncological effectiveness for both groups of patients.  Some background Intraoperative...

Read More

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Posted by on Mar 20, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk factors associated with acute radiation dermatitis (ARD; skin irritation) after radiotherapy (RT) in patients with breast cancer (BC). The data showed that patients with diabetes, smokers, and those with a body mass index (BMI; a measure of body weight in relation to height) of more than 25 kg/m2 had a...

Read More

Evaluating the long-term outcome of using gonadotropin-releasing hormone agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer.

Evaluating the long-term outcome of using gonadotropin-releasing hormone agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer.

Posted by on Jan 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of using gonadotropin-releasing hormone (GnRH) agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer (BC). The data showed that GnRH agonist use during chemotherapy was safe and effective to preserve ovarian function in these...

Read More

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Posted by on Dec 5, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of epirubicin (Ellence) and cyclophosphamide (Cytoxan) plus paclitaxel (Taxol)/docetaxel (Taxotere) (taxanes) (ECT) versus carboplatin (Paraplatin) plus taxanes (TP) regimens in patients with early-stage triple-negative breast cancer (TNBC). The data showed that both treatment regimens showed...

Read More

Evaluating the long-term benefits and risks of trastuzumab plus chemotherapy in patients with early-stage HER2+ breast cancer.

Evaluating the long-term benefits and risks of trastuzumab plus chemotherapy in patients with early-stage HER2+ breast cancer.

Posted by on Nov 7, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term benefits and risks of trastuzumab (Herceptin) plus chemotherapy in patients with early-stage HER2-positive (+) breast cancer (BC). The data showed that trastuzumab added to chemotherapy reduced the risk of BC recurrence and death for these patients. Some background BC is classified into different...

Read More

Evaluating the effects of adding chemotherapy to trastuzumab treatment on mental functioning in older patients with HER2-positive breast cancer.

Evaluating the effects of adding chemotherapy to trastuzumab treatment on mental functioning in older patients with HER2-positive breast cancer.

Posted by on Aug 29, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effects of adding chemotherapy to trastuzumab (Herceptin) treatment on cognitive (thinking and reasoning) functioning in older patients with HER2-positive (HER2+) breast cancer (BC). The data showed that the addition of chemotherapy did not impact cognitive functioning in these women. Some...

Read More

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study looked at the timing of chemotherapy (CT) after surgery in the treatment of early breast cancer (BC). The authors found that CT given within 31 days after surgery may improve survival in patients with triple-negative (TN) BC.  Some background BC is one of the most common types of cancer found in women. There are...

Read More